NEW YORK, July 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The 2012 US Cancer Diagnostics Market
http://www.reportlinker.com/p0365357/The-2012-US-Cancer-Diagnostics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics
This report presents a comprehensive analysis of the US cancer diagnostics market, including:
· Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.
· Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
· Ten-year test volume and sales forecasts for 40 cancer diagnostic procedures performed in US hospitals, commercial laboratories, physician offices and cancer clinics.
· Placements and installed base of automated and semiautomated analyzers used for cancer testing.
· Current instrumentation technologies and feature comparison of leading analyzers.
· Sales and market shares of leading suppliers.
· Emerging diagnostic technologies and their potential market applications.
· Product development opportunities.
· Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
· Business opportunities and strategic recommendations for suppliers.
Contains 620 pages and 103 tables
Table of Contents
Introduction
Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Brest Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
? Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Instrumentation Review And
Market Needs
1. Abbott AxSYM
2. Abbott Architect c4000
3. Abbott Architect i2000 Series
4. Abbott Architect ci8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra 400
12. Inverness DS2
13. J&J Vitros ECi/ECiQ
14. J&J Vitros 3600
15. J&J Vitros 5600
16. Olympus AU5400
17. Olympus AU3000i
18. Olympus AU2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus
30. Tosoh AIA-Series
31. Vital Diagnostics ATAC 8000
32. Vital Diagnostics Envoy 500
D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
- PCR
- DAP-PCR
- Immuno-PCR
- QC-PCR
- CAR
- DNA
- HPA
- LCR
- NASBA
- QBR
- SDA
- 3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas
Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
U.S.A.
A. Executive Summary
B. Business Environment
1. Health Care Expenditures
2. Cost Consciousness
3. Industry Consolidation
4. Managed Care
5. Hospitals
6. Admissions
7. Length of Stay
8. Industry Diversification
9. Physician Demographics
10. Population Aging
a. Chronic Illness
b. Disease Incidence
c. Susceptibility to Iatrogenesis
d. Multiple Illness Cases
11. Laboratory Regulations
C. Market Structure
1. Centralized Testing
a. Hospitals
b. Commercial/Private Laboratories
2. POT/Decentralized Testing
a. Physician Offices/Group Practices
b. Cancer Clinics
c. Point-Of-Care Testing
d. Other Decentralized Testing Locations
D. Market Size, Growth and Major Suppliers Sales,
Instrument Placements and Market Shares
Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria for Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Competitive Profiles
- Abbott
- AdnaGen
- Applied Gene Technologies
- Arca
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- Cepheid
- Correlogic Systems
- Dako
- Decode
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe
- Guided Therapeutics
- Hologic
- Ipsogen
- Kreatech
- Kyowa Medex
- Life Technologies
- Mackay Life Sciences
- Myriad Genetics
- Nanogen Elitech
- OncoLab
- Otho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila
Appendixes
Appendix I: Major Universities and Research
Centers Developing Cancer Diagnostic
Technology and Applications
Appendix II: Assumed Currency Exchange Rates
List of Tables
Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
Major Companies Developing or Marketing
HCG Tests
Major Companies Developing or Marketing
Insulin Tests
Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications
In Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: U.S., Total Tumor
Marker Test Volume and Sales Forecast by
Market Segment
U.S., Estimated New Cancer Cases and Deaths
U.S., Estimated Cancer Death Rates
Per 100,000 Population
U.S., Laboratories Performing Tumor
Marker Tests by Market Segment
U.S., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.S., Commercial/Private Laboratories
Performing Tumor Marker Tests by
Annual Test Volume
U.S., Physician Office Laboratories
Performing Tumor Marker Tests by
Practice Size
U.S., Total Tumor Marker Test Volume
Forecast by Market Segment-201
U.S., All Market Segments Major
Tumor Marker Test Volume Forecast
U.S., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Test Volume
Forecast
U.S., Physician Offices/Group Practices
Major Tumor Marker Test Volume
Forecast
U.S., Cancer Clinics Major Tumor
Marker Test Volume Forecast by Test
U.S., Total Tumor Marker Sales
Forecast by Market Segment
U.S., All Market Segment Major Tumor
Marker Sales Forecast by Test
U.S., Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by
Test
U.S., Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by
Test
U.S., Cancer Clinics Major Tumor
Marker Sales Forecast by Test
U.S., ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., AFP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Beta-2 Microglobulin Test Volume
And Diagnostics Sales Forecast by Market
Segment
U.S., CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Calcitonin Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., CEA Test Volume and Diagnostics
Sales by Market Segment
U.S., Chromogranin Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Colon-specific Antigen Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Cytokeratins Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Interferons Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Interleukins Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Occult Blood Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Oncogenes Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Sialic Acid Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thyroglobulin Test
Volume and Diagnostics
Sales Forecast by Market Segment
U.S., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Total Tumor Marker Sales
By Major Supplier
U.S., ACTH Testing Market Diagnostics
Sales by Major Supplier
U.S., AFP Testing Market Diagnostics
Sales by Major Supplier
U.S., Beta-2 Migroblolulin Testing Market
Diagnostics Sales by Major Supplier
U.S., CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics
Sales by Major Supplier
U.S., CEA Testing Market Diagnostics
Sales by Major Supplier
U.S., Ferritin Testing Market
Diagnostics Sales by Major Supplier
U.S., HCG Testing Market
Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market
Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing
Market Diagnostics Sales by Major Supplier
U.S., PAP Testing Market Diagnostics
Sales by Major Supplier
U.S., Progesterone Receptor Testing Market
Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics
Sales by Major Supplier
To order this report:
Diagnostics Industry: The 2012 US Cancer Diagnostics Market
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article